Tolerance by engaging antigen during cellular homeostasis

(

TEACH

)

ITN Protocol #:

ITN062ST

Branded Name:

TEACH

ClinicalTrials.Gov ID:

NCT03504241

Treatment Protocol #:

Therapeutic Area:

Transplantation

Current Status:

Follow-up

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients

Clinical Operations Associate Director

Clinical Operations Manager

ITN Biologist

ITN Biostat

ITN Clinical Trial Physician

NIAID Project Manager

Rho Scientist

PPD Lead Monitor

Study Personnel:

Protocol Chair

Allan Kirk, MD PhD allan.kirk@duke.edu

Work:

919-681-3445

Protocol Chair

Michele DesMarais mdesmarais@immunetolerance.org

Work:

415-420-4250

Protocol Chair

Allison Dias adias@immunetolerance.org

Work:

415-854-9199

Protocol Chair

Juliete Francisco Da Silva, PhD jsilva@immunetolerance.org

Work:

205-960-1065

Protocol Chair

Noha Lim, PhD nlim@immunetolerance.org

Work:

240-235-6151

Protocol Chair

Sindhu Chandran, MD schandran@immunetolerance.org

Work:

415-610-4284

Protocol Chair

Merideth Brown Shifflett brownmeri@niaid.nih.gov

Work:

240-627-3483

Protocol Chair

Theresa Scocca Theresa_Scocca@rhoworld.com

Work:

919-595-6312

Protocol Chair

Megan Carter megan.carter@ppdi.com

Work:

(910) 558-6490